Continental Divide? The Attitudes of US and Canadian Oncologists on the Costs, Cost-Effectiveness, and Health Policies Associated With New Cancer Drugs
- 20 September 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (27), 4149-4153
- https://doi.org/10.1200/jco.2010.29.1625
Abstract
Purpose Oncologists in the United States and Canada work in different health care systems, but physicians in both countries face challenges posed by the rising costs of cancer drugs. We compared their attitudes regarding the costs and cost-effectiveness of medications and related health policy. Methods Survey responses of a random sample of 1,355 United States and 238 Canadian medical oncologists (all outside of Québec) were compared. Results Response rate was 59%. More US oncologists (67% v 52%; P < .001) favor access to effective treatments regardless of cost, while more Canadians favor access to effective treatments only if they are cost-effective (75% v 58%; P < .001). Most (84% US, 80% Canadian) oncologists state that patient out-of-pocket costs influence their treatment recommendations, but less than half the respondents always or frequently discuss the costs of treatments with their patients. The majority of oncologists favor more use of cost-effectiveness data in coverage decisions (80% US, 69% Canadian; P = .004), but fewer than half the oncologists in both countries feel well equipped to use cost-effectiveness information. Majorities of oncologists favor government price controls (57% US, 68% Canadian; P = .01), but less than half favor more cost-sharing by patients (29% US, 41% Canadian; P = .004). Oncologists in both countries prefer to have physicians and nonprofit agencies determine whether drugs provide good value. Conclusion Oncologists in the United States and Canada generally have similar attitudes regarding cancer drug costs, cost-effectiveness, and associated policies, despite practicing in different health care systems. The results support providing education to help oncologists in both countries use cost-effectiveness information and discuss drug costs with their patients.Keywords
This publication has 14 references indexed in Scilit:
- Cancer Therapy Costs Influence Treatment: A National Survey Of OncologistsHealth Affairs, 2010
- American Society of Clinical Oncology Guidance Statement: The Cost of Cancer CareJournal of Clinical Oncology, 2009
- Challenges and Opportunities for Use of Cost-Effectiveness AnalysisJNCI Journal of the National Cancer Institute, 2009
- The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative studyBMC Health Services Research, 2007
- Cost issues in new disease-modifying treatments for advanced cancer: In-depth interviews with physiciansEuropean Journal Of Cancer, 2007
- Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot SurveyJournal of Clinical Oncology, 2007
- Do Oncologists Believe New Cancer Drugs Offer Good Value?The Oncologist, 2006
- Do oncologists discuss expensive anti-cancer drugs with their patients?Annals Of Oncology, 2006
- The Price Tag on Progress — Chemotherapy for Colorectal CancerNew England Journal of Medicine, 2004
- The Unbearable Rightness of Bedside RationingArchives of Internal Medicine, 1995